Capital Fund Management (CFM)’s Rhythm Pharmaceuticals RYTM Stock Holding History

Capital Fund Management (CFM)’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.61M	Buy	+68,548	New	+$6.2M	0.03%	713

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Fund Management (CFM)'s RYTM Position: Q2 2026 in Review

Capital Fund Management (CFM) opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 68,548 shares worth $7.61M. The stake represents 0.03% of the portfolio and ranks #713 among its holdings.

303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Capital Fund Management (CFM) held 68,548 shares of Rhythm Pharmaceuticals worth $7.61M as of Q2 2026.
Rhythm Pharmaceuticals was a new Capital Fund Management (CFM) position in Q2 2026.
Rhythm Pharmaceuticals made up 0.03% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #713 holding.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.